XTX Topco Ltd Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Key Points

• XTX Topco Ltd has acquired a new position in Madrigal Pharmaceuticals, purchasing 1,184 shares valued at approximately $392,000.
• The stock has seen significant investor interest, with several large investors, including FMR LLC and Woodline Partners LP, boosting their holdings in Madrigal Pharmaceuticals during the fourth quarter.
• Madrigal Pharmaceuticals recently reported earnings, beating consensus estimates with an EPS of ($1.90) and revenue up 1357.5% year-over-year, signaling strong growth potential.

XTX Topco Ltd purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,184 shares of the biopharmaceutical company's stock, valued at approximately $392,000.

Several other large investors have also recently added to or reduced their stakes in the company. VSM Wealth Advisory LLC bought a new position in Madrigal Pharmaceuticals in the 1st quarter valued at $25,000. Farther Finance Advisors LLC boosted its position in Madrigal Pharmaceuticals by 825.0% in the 1st quarter. Farther Finance Advisors LLC now owns 111 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 99 shares during the last quarter. GAMMA Investing LLC boosted its position in Madrigal Pharmaceuticals by 131.4% in the 1st quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 67 shares during the last quarter. First Horizon Advisors Inc. boosted its position in Madrigal Pharmaceuticals by 38.9% in the 1st quarter. First Horizon Advisors Inc. now owns 157 shares of the biopharmaceutical company's stock valued at $52,000 after buying an additional 44 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in Madrigal Pharmaceuticals by 42.7% in the 1st quarter. Parallel Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 85 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.

Insider Activity at Madrigal Pharmaceuticals

In other news, Director Paul A. Friedman sold 1,400 shares of the stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $350.03, for a total value of $490,042.00. Following the completion of the sale, the director directly owned 187,164 shares of the company's stock, valued at $65,513,014.92. This represents a 0.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Rebecca Taub sold 1,000 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $350.00, for a total value of $350,000.00. Following the sale, the director directly owned 461,044 shares of the company's stock, valued at $161,365,400. The trade was a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,377 shares of company stock valued at $21,316,969. Company insiders own 21.50% of the company's stock.

Madrigal Pharmaceuticals Trading Up 2.7%

MDGL stock traded up $9.50 during midday trading on Tuesday, hitting $359.00. The stock had a trading volume of 488,614 shares, compared to its average volume of 376,245. Madrigal Pharmaceuticals, Inc. has a 1-year low of $200.63 and a 1-year high of $377.46. The company has a current ratio of 5.11, a quick ratio of 4.78 and a debt-to-equity ratio of 0.17. The business has a fifty day moving average price of $303.20 and a two-hundred day moving average price of $312.98. The firm has a market cap of $7.97 billion, a P/E ratio of -27.94 and a beta of -1.02.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) EPS for the quarter, beating the consensus estimate of ($3.48) by $1.58. Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%. The company had revenue of $212.80 million for the quarter, compared to analyst estimates of $158.94 million. During the same quarter in the prior year, the company earned ($7.10) EPS. The firm's revenue for the quarter was up 1357.5% compared to the same quarter last year. On average, sell-side analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. JMP Securities reissued a "market outperform" rating and set a $443.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Thursday, April 24th. B. Riley reaffirmed a "buy" rating and set a $460.00 price objective (up from $422.00) on shares of Madrigal Pharmaceuticals in a research report on Friday, May 2nd. Wall Street Zen raised Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, May 5th. UBS Group reaffirmed a "buy" rating and set a $523.00 price objective (up from $458.00) on shares of Madrigal Pharmaceuticals in a research report on Tuesday. Finally, Canaccord Genuity Group upped their price objective on Madrigal Pharmaceuticals from $420.00 to $428.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Madrigal Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $439.71.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.